U.S. Communications Stock News

NYSE:ORI
NYSE:ORIInsurance

Old Republic International (ORI) Valuation Check As Lodestar Claims & Risk Services Gains A Distinct Identity

Why Lodestar's New Identity Matters for Old Republic International (ORI) Old Republic International (ORI) is giving its third party administrator business a separate identity with the launch of Lodestar Claims & Risk Services as an independent brand and standalone operating company within the group. This move brings a clearer profile for a top 10 national TPA that already provides claims administration and risk services across all 50 states. It also opens up fresh questions about how this...
NasdaqGS:IQ
NasdaqGS:IQEntertainment

A Look At iQIYI (IQ) Valuation As New Wuhan Theme Park Expands Its IP Reach

iQIYI (IQ) has drawn fresh investor attention after announcing iQIYI LAND Wuhan, its fourth theme park and first integrated into an urban renewal project, which extends its content into physical cultural tourism experiences. See our latest analysis for iQIYI. The new Wuhan project comes after a mixed stretch for the stock, with a 7 day share price return of 9.45% and 30 day share price return of 13.01%, but a 1 year total shareholder return of 15.76% and 5 year total shareholder return of...
NYSE:TPC
NYSE:TPCConstruction

Is It Too Late To Consider Tutor Perini (TPC) After A 327% One-Year Surge?

If you are wondering whether Tutor Perini at around US$84 is still priced attractively after a strong run, you are not alone. That is exactly what this valuation focused review will unpack. The stock has posted returns of 0.7% over the last week, 21.7% over the last month, 21.7% year to date and 327.1% over the past year. This naturally raises questions about how much value is already reflected in the share price. Recent headlines around Tutor Perini have centered on the company winning and...
NasdaqGS:NDAQ
NasdaqGS:NDAQCapital Markets

Is Nasdaq (NDAQ) Pricing Reflect Recent Market Infrastructure And Data Growth Prospects?

If you are wondering whether Nasdaq stock is attractively priced at today's level, you are not alone. The answer depends on how you think about value. The share price last closed at US$87.78, with returns of 1.9% over the past week, 1.7% over the past month, a 9.2% decline year to date, and 25.7% over 1 year, 61.8% over 3 years, and 76.1% over 5 years. Together, these figures hint at shifting expectations around both growth potential and risk. Recent news around Nasdaq has focused on its...
NYSE:SMA
NYSE:SMASpecialized REITs

A Look At SmartStop Self Storage REIT’s (SMA) Valuation After Recent Share Price Gains

Why SmartStop Self Storage REIT is on investors’ radar SmartStop Self Storage REIT (SMA) has drawn attention after a period of recent share gains, with the stock up around 10% over the past month and about 3% in the past 3 months. At a recent closing price of $33.39 and a market value near $1.8b, SmartStop sits in the mid cap range for U.S. real estate, giving investors a sizeable but still focused exposure to the self storage segment. See our latest analysis for SmartStop Self Storage...
NYSE:TRU
NYSE:TRUProfessional Services

Is It Time To Reassess TransUnion (TRU) After The Recent Share Price Recovery?

If you are wondering whether TransUnion at around US$77.75 is offering fair value or an opportunity, the next sections break down what the current market price might be implying. The stock has moved 8.1% over the past week and 10.2% over the last 30 days, while returns sit at 10.6% over 1 year, 23.8% over 3 years, and a 20.7% decline over 5 years. This gives a mixed picture for anyone thinking about long term entry points. Recent coverage of TransUnion has focused on how investors are...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

A Look At ADMA Biologics (ADMA) Valuation After Analyst Downgrades And Channel Stuffing Allegations

ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of the company’s public response. See our latest analysis for ADMA Biologics. The recent short report and analyst downgrades come after a difficult stretch for ADMA’s share price, with a 30 day share price return of a 24.02% decline and a year to date share price return of a 39.15% decline, even...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

A Look At C.H. Robinson Worldwide (CHRW) Valuation After Recent Share Price Momentum

Why C.H. Robinson Worldwide is on investors’ radar today C.H. Robinson Worldwide (CHRW) has drawn attention after a period of solid recent returns, including roughly 12% year to date and about 10% over the past year. This performance has prompted closer scrutiny of its freight focused business. See our latest analysis for C.H. Robinson Worldwide. The recent move up to a share price of $183.95, supported by a 7 day share price return of 11.54% and a very large 1 year total shareholder return...
NasdaqGS:LGIH
NasdaqGS:LGIHConsumer Durables

A Look At LGI Homes (LGIH) Valuation After The Desert Edge Community Launch

LGI Homes (LGIH) has opened its Desert Edge community in Tooele County, Utah, a 700-home development featuring upgraded amenities and opening weekend incentives, providing investors with an additional data point on the stock. See our latest analysis for LGI Homes. The share price has moved sharply in the short term, with a 1 day share price return of 5.95% and a 30 day share price return of 34.78%. However, the 1 year total shareholder return of 17.74% and 5 year total shareholder return of...
NYSE:T
NYSE:TTelecom

A Look At AT&T (T) Valuation After Mixed Short And Long Term Shareholder Returns

What AT&T’s Recent Returns Say About Investor Sentiment AT&T (T) has attracted fresh attention after a mixed run in recent months, with the share price down about 7.5% over the past month but up roughly 11.6% in the past 3 months. Over the past year, the stock shows a total return of about 3.8%, with year to date performance around 6.6%. These returns sit alongside annual revenue of roughly US$125.6b and net income of about US$21.9b. See our latest analysis for AT&T. Recent trading shows a...
NYSE:JHG
NYSE:JHGCapital Markets

Is It Too Late To Consider Janus Henderson Group (JHG) After Its 1-Year Surge?

If you are wondering whether Janus Henderson Group is still reasonably priced after its strong run, this breakdown will help you frame what the current share price could mean for value. The stock closed at US$51.53 recently, with returns of 2.2% over 30 days, 7.8% year to date, 79.4% over 1 year, 123.5% over 3 years and 90.6% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on how Janus Henderson Group...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Alphabet Marvell Chip Talks Put AI Cloud Economics In Focus

Alphabet, ticker NasdaqGS:GOOGL, is reportedly in advanced talks with Marvell Technology to co develop two custom AI processors. The new chips are expected to focus on AI inference efficiency and memory processing for Google Cloud AI workloads. This move would deepen Alphabet's control over its AI hardware stack and adjust its relationships with existing silicon partners. For investors tracking NasdaqGS:GOOGL, this potential partnership comes with the shares at around $337.42 and a 1 year...
OTCPK:CCFN
OTCPK:CCFNBanks

Muncy Columbia Financial (OTCPK:CCFN) Earnings Growth Of 27.3% Shapes Expectations Ahead Of Q1 2026

Muncy Columbia Financial (OTCPK:CCFN) has put up another solid set of numbers, with Q4 2025 revenue at US$19.2 million, basic EPS of US$2.09, and net income of US$7.4 million heading into its Q1 2026 reporting period. Over recent quarters the bank has seen revenue move from US$15.5 million in Q4 2024 to US$19.2 million in Q4 2025, while quarterly EPS shifted from US$1.47 to US$2.09 over the same span, all feeding into trailing 12 month earnings growth of 27.3% and a net margin of 34.5%. Taken...
NasdaqCM:AHCO
NasdaqCM:AHCOHealthcare

Is AdaptHealth (AHCO) Pricing Reflect Its Recent 72.9% One Year Share Price Jump

To understand what AdaptHealth might be worth to you as an investor, it helps to separate the share price story from the underlying value story. That is what this article sets out to do. Over the past year, the stock has recorded a 72.9% return, with returns of 2.8% over 7 days, 27.9% over 30 days, and 31.0% year to date, while the 3 year return is 4.5% and the 5 year return is a 57.0% decline, indicating a mixed longer term picture. Recent company developments and sector sentiment shifts...
NasdaqGM:NNOX
NasdaqGM:NNOXHealthcare

Nano X Imaging (NNOX) Quarterly Losses Far Exceed US$3.4m Revenue Reinforcing Bearish Narratives

Nano-X Imaging (NNOX) has reported third quarter FY 2025 revenue of US$3.4 million with a basic EPS loss of US$0.21, alongside trailing twelve month revenue of US$12.3 million and a basic EPS loss of US$0.88. The company has seen quarterly revenue move from US$2.7 million in Q2 2024 to US$3.4 million in Q3 2025, while basic EPS has remained in a narrow loss range between roughly US$0.21 and US$0.23 per quarter. This keeps the focus on whether revenue can outgrow persistent losses and...
NYSE:CF
NYSE:CFChemicals

A Look At CF Industries Holdings (CF) Valuation After Strait Of Hormuz Fertilizer Supply Jitters

CF Industries Holdings (CF) is back in focus after geopolitical headlines around the Strait of Hormuz whipsawed expectations for global fertilizer flows and swung sentiment on ammonia and nitrogen supply risk within days. See our latest analysis for CF Industries Holdings. That geopolitical whiplash has fed into a sharp swing in sentiment, with CF Industries Holdings now trading at US$115.94 and showing a 90 day share price return of 31.12% and a 1 year total shareholder return of 57.91%...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

If You Believe In Robotics And Automation Stocks Then These Three Trajectories Could Define The Next Cycle

Robotics is moving from science project to real-world workhorse just as investors are juggling inflation worries, oil-price swings, and changing interest rate expectations across major economies. While bond yields, energy markets, and central bank signals keep shifting, the physical AI push is quietly about one thing you can understand very clearly: productivity. This screener focuses on robotics companies that are not just building hardware, but are structured to translate automation demand...
NasdaqCM:MNSB
NasdaqCM:MNSBBanks

MainStreet Bancshares (MNSB) Net Interest Margin Resilience Tests Bullish Narratives In Q1 2026

MainStreet Bancshares (MNSB) has followed up its move back into profitability with Q1 2026 results that sit against a recent run of steady quarterly revenue and earnings, capped most recently by Q4 2025 revenue of about US$17.7 million and basic EPS of US$0.46 on net income of US$3.5 million. Over the last few quarters, the company has seen total revenue move from US$13.3 million in Q3 2024 to US$17.4 million in Q1 2025 and then to US$17.7 million in Q4 2025. Over the same period, quarterly...
NasdaqGS:COO
NasdaqGS:COOMedical Equipment

Is Cooper Companies (COO) Now Attractive After Recent Share Price Weakness?

If you are wondering whether Cooper Companies is starting to look better value after a weaker share price, this article walks through the key numbers that matter to you. The stock last closed at US$69.46, with returns of a 3.1% decline over 7 days, a 0.7% decline over 30 days, a 14.4% decline year to date, and an 11.7% decline over 1 year. These moves may have changed how some investors view its risk and opportunity profile. Recent coverage has focused on Cooper Companies within the broader...
NasdaqGM:ISTR
NasdaqGM:ISTRBanks

Investar Holding (ISTR) Rising Net Interest Margin Reinforces Bullish Profitability Narratives

Investar Holding (ISTR) has just put fresh numbers on the table for Q1 2026, with recent quarters showing total revenue stepping from US$20.2 million in Q4 2024 to US$23.2 million in Q4 2025 and quarterly EPS ranging between about US$0.46 and US$0.64 over 2025. Over the same period, trailing twelve month EPS moved from US$2.06 to US$2.22 while revenue on this basis went from US$83.2 million to US$93.3 million, giving investors a clear line of sight on how the top line and per share earnings...
NYSE:RNR
NYSE:RNRInsurance

RenaissanceRe Holdings (RNR) Valuation Check After Recent Share Price Momentum

RenaissanceRe Holdings (RNR) continues to draw attention after recent trading, with the stock closing at US$312.80. Investors are weighing this price against the company’s recent returns and its role in global reinsurance. See our latest analysis for RenaissanceRe Holdings. While the latest 1 day share price return of 0.76% is softer, the 30 day share price return of 7.59% and year to date share price return of 14.90% sit alongside a 1 year total shareholder return of 34.03%. This may hint...
NasdaqGS:BANF
NasdaqGS:BANFBanks

Does BancFirst’s Q1 EPS Jump Signal a Stronger Profitability Trend for BANF?

BancFirst Corporation recently reported first-quarter 2026 results, with net income rising to US$63,000,000 from US$56,110,000 a year earlier and basic earnings per share increasing to US$1.88 from US$1.69. The simultaneous growth in net income and both basic and diluted earnings per share highlights improving profitability across BancFirst’s ongoing operations. Next, we will examine how BancFirst’s higher earnings per share shapes the company’s investment narrative and longer-term business...
NYSE:EVEX
NYSE:EVEXAerospace & Defense

Can Eve (EVEX) Turning 50 eVTOL Test Flights Into Certifiable Prototypes Reshape Its Moat?

In April 2026, Eve Air Mobility reported that its full-scale eVTOL engineering prototype has now completed 50 successful test flights since its first flight on December 19, 2025, generating over two hours of high-fidelity performance and systems data as it advances toward certification with Brazil’s aviation authority, ANAC. This milestone underscores Eve’s integrated development approach, combining Embraer-derived aircraft engineering with coordinated planning for operators, cities,...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision

Pfizer and Astellas received FDA Priority Review for PADCEV plus Keytruda as a perioperative treatment for muscle invasive bladder cancer. The application covers patients regardless of cisplatin eligibility, broadening the potential treated population. The filing is backed by Phase 3 data that showed improved outcomes, including lower risks of death and cancer recurrence. For investors watching Pfizer, NYSE:PFE, this Priority Review adds a fresh data point beyond recent debates about...